Colony Group’s Teva Pharmaceuticals TEVA Stock Holding History

Colony Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-153,720	Closed	-$7.07M	–	295
2016 Q3	$7.07M	Sell	153,720 -7,070	-4%	-$369K	0.79%	50
2016 Q2	$8.08M	Buy	160,790 +4,240	+3%	+$226K	0.89%	46
2016 Q1	$8.38M	Sell	156,550 -1,950	-1%	-$114K	0.97%	41
2015 Q4	$10.4M	Buy	158,500 +151,588	+2,193%	+$9.37M	0.95%	35
2015 Q3	$390K	Buy	6,912 +2,085	+43%	+$135K	0.05%	265
2015 Q2	$285K	Buy	4,827 +4,640	+2,481%	+$286K	0.03%	305
2015 Q1	$12K	Sell	187 -4,100	-96%	-$238K	﹤0.01%	550
2014 Q4	$247K	Buy	4,287 +4,000	+1,394%	+$223K	0.03%	314
2014 Q3	$15K	Hold	287	–	–	﹤0.01%	551
2014 Q2	$15K	Sell	287 -1,792	-86%	-$91.6K	﹤0.01%	475
2014 Q1	$110K	Buy	2,079 +192	+10%	+$8.87K	0.01%	260
2013 Q4	$76K	Buy	+1,887	New	+$74.3K	0.01%	289

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Colony Group's TEVA Position: Q4 2016 in Review

Colony Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 153,720 shares — an estimated $7.07M sold.

Colony Group first reported a position in TEVA in Q4 2013 and held it in 12 quarters. The position peaked at $10.4M in Q4 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Colony Group reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Colony Group sold 153,720 Teva Pharmaceuticals shares in Q4 2016, an estimated $7.07M.
Colony Group first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Colony Group's Teva Pharmaceuticals position peaked at $10.4M in Q4 2015.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Colony Group's 13F filing for Q4 2016, filed 16 Feb 2017.